Simcyp Papers RSS Feed

Abduljalil K et al.

Thu, 19 Apr 2012 00:00:00 GMT

Anatomical, physiological and metabolice changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clinical Pharmacokinetics 51, 365-396, June 2012

Polak S et al.

Thu, 19 Apr 2012 00:00:00 GMT

Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. Journal of Pharmaceutical Sciences E-Publication Ahead Of Print, 2012

Darwich AS et al.

Fri, 30 Mar 2012 00:00:00 GMT

Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol E-Publication Ahead Of Print, 2012

Lu Gaohua et al.

Thu, 22 Mar 2012 00:00:00 GMT

Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. Current Drug Metabolism E-Publication Ahead Of Print, 2012

Chetty M et al.

Thu, 22 Mar 2012 00:00:00 GMT

Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Current Drug Metabolism E-Publication Ahead Of Print, 2012

Plowchalk DR & Rowland-Yeo K

Thu, 19 Jan 2012 00:00:00 GMT

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. European Journal of Clinical Pharmacology E-Publication Ahead Of Print, 2012

Ohtani H et al.

Tue, 20 Dec 2011 00:00:00 GMT

Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics & Drug Disposition 32, 498-506, December 2011

Ghobadi C et al.

Thu, 1 Dec 2011 00:00:00 GMT

Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clinical Pharmacokinetics 50, 809-822, December 2011

Crewe HK et al.

Mon, 4 Jul 2011 00:00:00 GMT

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P4502C9? A systematic investigation into inter-system extrapolation factors. Biopharmaceutics & Drug Disposition 32, 303-318, September 2011

Rowland-Yeo K et al.

Tue, 14 Jun 2011 00:00:00 GMT

Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. European Journal of Pharmaceutical Sciences 43, 160-173, June 2011

Rowland-Yeo K et al.

Mon, 28 Mar 2011 00:00:00 GMT

Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Reviews In Clinical Pharmacology 4, 261-274, March 2011

Cubitt HE et al.

Thu, 24 Mar 2011 00:00:00 GMT

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41, 623-638, August 2011

Johnson T & Rostami-Hodjegan A

Tue, 1 Mar 2011 00:00:00 GMT

Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatric Anesthesia 21, 291-301, March 2011

Rowland M et al.

Tue, 1 Feb 2011 00:00:00 GMT

Physiologically-based pharmacokinetics in drug development and regulatory science. Annual Reviews of Pharmacology & Toxicology 51, 45-73, February 2011

Barter ZE et al.

Tue, 30 Nov 2010 00:00:00 GMT

Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharmaceutics & Drug Disposition 31, 516-532, November 2010

Darwich AS et al.

Mon, 1 Nov 2010 00:00:00 GMT

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Current Drug Metabolism 11, 716-729, November 2010

Bois FY et al.

Tue, 1 Jun 2010 00:00:00 GMT

PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 106, 154-161, June 2010

Johnson TN et al.

Mon, 1 Mar 2010 00:00:00 GMT

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clinical Pharmacokinetics 49, 189-206, March 2010

Rowland-Yeo K et al.

Mon, 1 Mar 2010 00:00:00 GMT

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. European Journal of Pharmaceutical Sciences 39, 298-309, March 2010

Johnson TN et al.

Fri, 10 Jul 2009 00:00:00 GMT

Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharmaceutical Statistics 8, 186-202, July-September 2009

Jamei M et al.

Mon, 1 Jun 2009 00:00:00 GMT

Population-based mechanistic prediction of oral drug absorption. The AAPS Journal 11, 225-237, June 2009

Almond LM et al.

Fri, 1 May 2009 00:00:00 GMT

Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Current Drug Metabolism 10, 420-432, May 2009

Jamei M et al.

Mon, 9 Feb 2009 00:00:00 GMT

The Simcyp® population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology 5, 211-223, February 2009

Van LM et al.

Mon, 26 Jan 2009 00:00:00 GMT

Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism.
Journal of Pharmaceutical Sciences 98, 763-771, February 2009

Jamei M et al.

Thu, 1 Jan 2009 00:00:00 GMT

A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘Bottom-Up’ vs ‘Top-Down’ recognition of covariates. Drug Metabolism & Pharmacokinetics 24, 53-75, 2009

Ghobadi C et al.

Mon, 1 Dec 2008 00:00:00 GMT

CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metabolism & Pharmacokinetics 23, 101-105, April 2008

Barter ZE et al.

Mon, 1 Dec 2008 00:00:00 GMT

Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metabolism & Disposition 36, 2405-2409, December 2008

Johnson TN & Thomson M

Mon, 21 Jul 2008 00:00:00 GMT

Intestinal metabolism and transport of drugs in children: the effects of age
and disease.
Journal of Pediatric Gastroenterology & Nutrition 47, 3-10, July 2008

Johnson TN

Mon, 21 Jul 2008 00:00:00 GMT

The problems in scaling adult drug doses to children.
Archives of Disease in Childhood 93, 207-211, March 2008

Yang J et al.

Wed, 25 Jun 2008 00:00:00 GMT

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current Drug Metabolism 9, 384-394, June 2008

Johnson TJ et al.

Thu, 1 May 2008 00:00:00 GMT

Development of CYP2D6 and CYP3A4 in the first year of life. Clinical Pharmacology & Therapeutics 83, 670-671, May 2008

Perrett HP et al.

Fri, 12 Oct 2007 00:00:00 GMT

Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes. Drug Metabolism & Disposition 35, 1733-1736, October 2007

Yang J et al.

Tue, 2 Oct 2007 00:00:00 GMT

Prediction of intestinal first-pass drug metabolism. Current Drug Metabolism 8, 676-684, October 2007

Yang J et al.

Mon, 11 Jun 2007 00:00:00 GMT

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.
European Journal of Pharmaceutical Sciences 31, 232-241, July 2007

Van LM et al.

Tue, 22 May 2007 00:00:00 GMT

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. European Journal of Pharmaceutical Sciences 32, 8-16, September 2007

Yang J et al.

Tue, 6 Mar 2007 00:00:00 GMT

Misuse of the well-stirred model of hepatic drug clearance. Drug Metabolism & Disposition 35, 501-502, March 2007

Van LM et al.

Mon, 19 Feb 2007 00:00:00 GMT

Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). European Journal of Pharmaceutical Sciences 31, 53-61, May 2007

Dickinson GL et al.

Mon, 29 Jan 2007 00:00:00 GMT

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example. British Journal of Clinical Pharmacology 64, 14-26, July 2007

Rostami-Hodjegan A & Tucker GT

Mon, 29 Jan 2007 00:00:00 GMT

Simulation and prediction of in vivo metabolic drug clearance from in vitro data. Nature Reviews Drug Discovery 6, 140-148, February 2007

Dickinson GL et al.

Tue, 2 Jan 2007 00:00:00 GMT

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphisms on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. Journal of Clinical Pharmacology 47, 175-186, February 2007

Barter ZE et al.

Tue, 2 Jan 2007 00:00:00 GMT

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current Drug Metabolism 8, 33-45, January 2007

Christensen H et al.

Fri, 1 Dec 2006 00:00:00 GMT

Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. Journal of Pharmaceutical Sciences 95, 2778-2787, December 2006

Johnson TN et al.

Thu, 30 Nov 2006 00:00:00 GMT

Prediction of clearance of eleven drugs and associated variability in neonates, infants and children. Clinical Pharmacokinetics 45, 931-956, September 2006

Van LM et al.

Wed, 1 Nov 2006 00:00:00 GMT

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). Journal of Psychopharmacology 20, 834-841, November 2006

Yang J et al.

Wed, 1 Nov 2006 00:00:00 GMT

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. Journal of Psychopharmacology 20, 842-849, November 2006

Shiran MR et al.

Sat, 1 Jul 2006 00:00:00 GMT

Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. Xenobiotica 36, 567-580, July 2006

Inoue S et al.

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
II: Potential inter-ethnic differences. Xenobiotica 36, 499-513, June 2006

Howgate EM et al.

Thu, 1 Jun 2006 00:00:00 GMT

Prediction of in vivo drug clearance from in vitro data.
I: Impact of inter-individual variability. Xenobiotica 36, 473-497, June 2006

Ghanbari F et al.

Sat, 1 Apr 2006 00:00:00 GMT

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Current Drug Metabolism 7, 315-334, April 2006

Johnson TN et al.

Thu, 1 Dec 2005 00:00:00 GMT

Changes in liver volume from birth to adulthood: a meta analysis. Liver Transplantation 12, 1481-1493, December 2005

Yang J et al.

Tue, 1 Nov 2005 00:00:00 GMT

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. European Journal of Pharmaceutical Sciences 26, 334-340, November 2005

Johnson TN

Wed, 1 Jun 2005 00:00:00 GMT

Modelling approaches to dose estimation in children. British Journal of Clinical Pharmacology 59, 663-669, June 2005

Rostami-Hodjegan A & Tucker GT

Wed, 1 Dec 2004 00:00:00 GMT

In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discovery Today: Technologies 1, 441-448, December 2004

Özdemir M et al.

Wed, 1 Dec 2004 00:00:00 GMT

Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. Journal of Clinical Pharmacology 44, 1398-1404, December 2004

Johnson TN et al.

Wed, 1 Dec 2004 00:00:00 GMT

Prediction of drug clearance from in vitro data for 10 drugs in neonates, infants and children using Simcyp. Drug Metabolism Reviews 36, Supplement 1, A680, 340, December 2004

Rowland-Yeo K et al.

Wed, 1 Dec 2004 00:00:00 GMT

Predicting the clearance of CYP2C9 substrates. Drug Metabolism & Disposition 32, 1522-1523, December 2004

Tucker GT

Fri, 1 Oct 2004 00:00:00 GMT

Predicting drug-drug interactions: in vitro veritas?
EUFEPS 2004 - 8th European Congress of Pharmaceutical Sciences October 17th-20th 2004, Brussels, Belgium.
Abstract published in: European Journal of Pharmaceutical Sciences 23, SS5-3, 13, October 2004

Yang J et al.

Fri, 1 Oct 2004 00:00:00 GMT

Cytochrome P450 3A expression and activity in the human small intestine. Clinical Pharmacology & Therapeutics 76, 391, October 2004

Tucker GT

Thu, 1 Jul 2004 00:00:00 GMT

Pharmacogenetics - expectations and reality. British Medical Journal 329, 4-6, July 2004

Johnson TN et al.

Sat, 1 May 2004 00:00:00 GMT

A comparison of methods to predict drug clearance in neonates,
infants and children.
Proceedings of the British Pharmacological Society December 16th-18th 2003, GKT School of Biomedical Sciences,
King’s College London, Guy’s Campus.
Abstract published in: British Journal of Clinical Pharmacology 57, A23, 677-678, May 2004

Johnson TN et al.

Sat, 1 May 2004 00:00:00 GMT

Prediction of drug clearance and its variability in neonates, infants and
children using Simcyp. European Society for Developmental, Perinatal and Paediatric
Pharmacology, 9th Congress June 16th-19th 2004, Marburg, Germany.
Abstract published in: Paediatric and Perinatal Drug Therapy 6, L23, 51, May 2004

Proctor NJ et al.

Sun, 1 Feb 2004 00:00:00 GMT

Prediction of clearance from recombinantly expressed CYPs: Intersystem extrapolation factor (ISEF). Xenobiotica 34, 151-178, February 2004

Proctor NJ et al.

Mon, 1 Dec 2003 00:00:00 GMT

Sources of variability associated with quantitative predictions of drug clearance from recombinant CYP enzymes. Drug Metabolism Reviews 35, Supplement 1, A202, 101, April 2003

Wilson ZE et al.

Mon, 1 Dec 2003 00:00:00 GMT

Reference values for the amount of microsomal protein and number of hepatocytes per gram of human liver. Drug Metabolism Reviews 35, Supplement 1, A200, 100, April 2003

Rowland-Yeo K et al.

Mon, 1 Dec 2003 00:00:00 GMT

Abundance of cytochromes P450 in human liver: a meta-analysis.
British Pharmacological Society Winter Meeting
University of London, December 2003

Wilson ZE et al.

Wed, 1 Oct 2003 00:00:00 GMT

Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. British Journal of Clinical Pharmacology 56, 433-440, October 2003

Yang J et al.

Wed, 1 Oct 2003 00:00:00 GMT

The effects of dose staggering on metabolic drug-drug interactions. European Journal of Pharmaceutical Sciences 20, 223-232, October 2003

Moghadamnia AA et al.

Tue, 1 Jul 2003 00:00:00 GMT

Physiologically based modelling of inhibition of metabolism to assess the relative potency of drug and metabolite: dextromethorphan vs dextrorphan using quinidine Inhibition. British Journal of Clinical Pharmacology 56, 57-67, July 2003

Johnson TN et al.

Tue, 1 Apr 2003 00:00:00 GMT

Prediction of age related changes in midazolam clearance in children
using SIMCYP.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology 55, A26, 432-433, April 2003

Proctor NJ et al.

Tue, 1 Apr 2003 00:00:00 GMT

In vitro prediction of population in vivo drug clearance using updated
scaling factors.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology 55, A49, 445, April 2003

Proctor NJ et al.

Tue, 1 Apr 2003 00:00:00 GMT

ISEF: an intersystem extrapolation factor for use with recombinant cytochrome P450 expressed systems.
Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology 55, A35, 437-438, April 2003

Wilson ZE et al.

Tue, 1 Apr 2003 00:00:00 GMT

Determining values for human microsomal protein per gram of liver. Proceedings of the British Pharmacological Society January 7th-10th 2003, William Harvey Research Institute, Bart’s and the London, Queen Mary’s School of Medicine and Dentistry.
Abstract published in: British Journal of Clinical Pharmacology 55, A2, 418-419, April 2003

Tooley A et al.

Wed, 1 Dec 1999 00:00:00 GMT

Acute inhibition of methadone metabolism by ritonavir: projection of interaindividual variability from in vitro data. Proceedings of the British Pharmaceutical Society July 14th-16th 1999, University of Nottingham. Abstract published in: British Journal of Clinical Pharmacology 48, A16, 883-884, 1999

Rostami-Hodjegan A et al.

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity. Proceedings of the British Pharmaceutical Society January 6th-8th 1999, Stakis Metropole Hotel, Brighton (King's College London). Abstract published in: British Journal of Clinical Pharmacology 47, A4, 577-578, 1999

Rostami-Hodjegan A et al.

Tue, 1 Jun 1999 00:00:00 GMT

In vivo indices of enzyme activity-the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9, 277-286, June 1999

Tucker GT et al.

Tue, 1 Dec 1998 00:00:00 GMT

The determination of drug metabolising enzyme activity in vivo: pharmacokinetics and statistical issues. Xenobiotica 28, 1255-1273, December 1998

Rostami-Hodjegan A et al.

Sun, 1 Dec 1996 00:00:00 GMT

Caffeine metabolic ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 6, 121-49, April 1996